Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
08 mai 2023 08h00 HE
|
Eyenovia, Inc.
Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia’s proprietary development...
Eyenovia to Report First Quarter 2023 Results on Thursday, May 11
04 mai 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
Eyenovia Announces Poster Presentation at ARVO 2023
24 avr. 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
30 mars 2023 16h05 HE
|
Eyenovia, Inc.
Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia...
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
23 mars 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with...
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
28 févr. 2023 16h05 HE
|
Eyenovia, Inc.
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
15 févr. 2023 09h51 HE
|
Eyenovia, Inc.
NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops
12 janv. 2023 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
Eyenovia Announces Participation at the 2023 International Consumer Electronics Show
20 déc. 2022 08h00 HE
|
Eyenovia, Inc.
Booth to feature “smart” remote patient monitoring capabilities being developed for future versions of the company’s novel Optejet® drug delivery technology Company to occupy booth 8311 NEW YORK,...
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
13 déc. 2022 08h00 HE
|
Eyenovia, Inc.
Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel Optejet® drug delivery technology Company also announced receipt of...